MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advances
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
6 stories
MBX said its pivotal canvuparatide trial is dosing patients, MBX 4291 data remain on track for Q4 2026, and cash on hand extends into 2029.
SEC filing, FDA (9)
The ultra-rare disease company plans to use proceeds to fund commercialization preparation for its hyperinsulinism antibody ersodetug.
SEC filing
Preliminary data from a November 5 analysis show 13 of 16 patients met the responder criterion, with full topline results expected by mid-December 2026.
SEC filing
Rezolute said the FDA recommended it file a Biologics License Application for congenital hyperinsulinism, while topline results from its Phase 3 upLIFT study in tumor HI are expected by mid-December 2026.
SEC filing
The agency's recommendation follows its review of additional data from the Phase 3 sunRIZE study of ersodetug, which did not meet its primary or key secondary endpoints.
SEC filing
The company reported interim upLIFT progress, an ongoing FDA review of the sunRIZE congenital HI data, and $107.8 million in cash and investments as of June 30, 2026.
SEC filing